RU2007113156A - SOLID NANOCOMPOSITION FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES - Google Patents

SOLID NANOCOMPOSITION FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES Download PDF

Info

Publication number
RU2007113156A
RU2007113156A RU2007113156/15A RU2007113156A RU2007113156A RU 2007113156 A RU2007113156 A RU 2007113156A RU 2007113156/15 A RU2007113156/15 A RU 2007113156/15A RU 2007113156 A RU2007113156 A RU 2007113156A RU 2007113156 A RU2007113156 A RU 2007113156A
Authority
RU
Russia
Prior art keywords
polymer
kollidon
hydrophobic
polyvinylpyrrolidone
inert
Prior art date
Application number
RU2007113156/15A
Other languages
Russian (ru)
Other versions
RU2351352C2 (en
Inventor
Ольга Николаевна Пожарицкая (RU)
Ольга Николаевна Пожарицкая
Ирина Николаевна Уракова (RU)
Ирина Николаевна Уракова
Александр Николаевич Шиков (RU)
Александр Николаевич ШИКОВ
Валерий Геннадьевич Макаров (RU)
Валерий Геннадьевич Макаров
Марина Николаевна Макарова (RU)
Марина Николаевна Макарова
Владимир Петрович Тихонов (RU)
Владимир Петрович Тихонов
Original Assignee
Закрытое акционерное общество "Санкт-Петербургский институт фармации" (RU)
Закрытое акционерное общество "Санкт-Петербургский институт фармации"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое акционерное общество "Санкт-Петербургский институт фармации" (RU), Закрытое акционерное общество "Санкт-Петербургский институт фармации" filed Critical Закрытое акционерное общество "Санкт-Петербургский институт фармации" (RU)
Priority to RU2007113156/15A priority Critical patent/RU2351352C2/en
Priority to PCT/RU2008/000201 priority patent/WO2008123798A1/en
Publication of RU2007113156A publication Critical patent/RU2007113156A/en
Application granted granted Critical
Publication of RU2351352C2 publication Critical patent/RU2351352C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Твердая нанокомпозиция для доставки биологически активных веществ, содержащая 0,1-15% активного компонента, 40-95% полимера, 0-6% гидрофобного или инертного полимера и 0-56% водорастворимого компонента, отличающаяся тем, что содержит до 15% активного компонента, в качестве которого выступает таксифолин, 40-95% полимера, в качестве которого используют арабиногалактан, полиэтиленгликоли, поливинилпирролидоны и поливинолы различных молекулярных масс, 0-56% водорастворимого полимера, выбираемого из ряда возможных наполнителей: kollidon VA64 (сополимер винилпирролидона и винилацетата), kollidon 90F (высокомолекулярный поливинилпирролидон с М.м. 1000000-1500000), ludipress (модифицированная лактоза), сахарная пудра, изомальтоза, 0-6% гидрофобного или инертного полимера с целью достижения контролируемого высвобождения лекарственного вещества, где в качестве гидрофобного компонента используют compritol 888 АТО, Gatefosse (композиция моно-, ди- и триглицеридов бегеновой кислоты), в качестве инертного - kollidon SR, Basf (смесь полимеров поливинилпирролидона и поливинилацетата).2. Нанокомпозиция по п.1, в которой в качестве полимера использован полиэтиленгликоль (ПЭГ) (М.м. от 4000 до 8000), вносимый в систему при различных соотношениях с активным веществом.3. Нанокомпозиция по п.1, в которой в качестве полимера использован поливинилпирролидон (ПВП) (М.м. от 7000 до 20000), вносимый в систему при различных соотношениях с активным веществом.4. Нанокомпозиция по п.1, в которой в качестве полимера использован полисахарид арабиногалактан, вносимый в систему при различных соотношениях с активным веществом1. Solid nanocomposite for the delivery of biologically active substances, containing 0.1-15% of the active component, 40-95% of the polymer, 0-6% of a hydrophobic or inert polymer and 0-56% of a water-soluble component, characterized in that it contains up to 15% the active component, which is taxifolin, 40-95% of the polymer, which is used arabinogalactan, polyethylene glycols, polyvinylpyrrolidones and polyvinyls of various molecular weights, 0-56% water-soluble polymer, selected from a number of possible fillers: kollidon VA64 (vinyl copolymer irrolidone and vinyl acetate), kollidon 90F (high molecular weight polyvinylpyrrolidone with M.M. 1,000,000 to 1,500,000), ludipress (modified lactose), powdered sugar, isomaltose, 0-6% hydrophobic or inert polymer in order to achieve controlled release of the drug substance, where as the hydrophobic component uses compritol 888 ATO, Gatefosse (a composition of mono-, di- and triglycerides of behenic acid), as inert - kollidon SR, Basf (a mixture of polymers of polyvinylpyrrolidone and polyvinyl acetate) .2. The nanocomposite according to claim 1, in which polyethylene glycol (PEG) is used as the polymer (M.m. from 4000 to 8000), introduced into the system at various ratios with the active substance. The nanocomposition according to claim 1, in which polyvinylpyrrolidone (PVP) (M.M. from 7000 to 20,000) is used as a polymer, introduced into the system at various ratios with the active substance. The nanocomposite according to claim 1, in which the arabinogalactan polysaccharide used as a polymer is introduced into the system at various ratios with the active substance

Claims (4)

1. Твердая нанокомпозиция для доставки биологически активных веществ, содержащая 0,1-15% активного компонента, 40-95% полимера, 0-6% гидрофобного или инертного полимера и 0-56% водорастворимого компонента, отличающаяся тем, что содержит до 15% активного компонента, в качестве которого выступает таксифолин, 40-95% полимера, в качестве которого используют арабиногалактан, полиэтиленгликоли, поливинилпирролидоны и поливинолы различных молекулярных масс, 0-56% водорастворимого полимера, выбираемого из ряда возможных наполнителей: kollidon VA64 (сополимер винилпирролидона и винилацетата), kollidon 90F (высокомолекулярный поливинилпирролидон с М.м. 1000000-1500000), ludipress (модифицированная лактоза), сахарная пудра, изомальтоза, 0-6% гидрофобного или инертного полимера с целью достижения контролируемого высвобождения лекарственного вещества, где в качестве гидрофобного компонента используют compritol 888 АТО, Gatefosse (композиция моно-, ди- и триглицеридов бегеновой кислоты), в качестве инертного - kollidon SR, Basf (смесь полимеров поливинилпирролидона и поливинилацетата).1. A solid nanocomposite for the delivery of biologically active substances, containing 0.1-15% of the active component, 40-95% of the polymer, 0-6% of a hydrophobic or inert polymer and 0-56% of a water-soluble component, characterized in that it contains up to 15% the active component, which is taxifolin, 40-95% of the polymer, which is used arabinogalactan, polyethylene glycols, polyvinylpyrrolidones and polyvinyls of various molecular weights, 0-56% water-soluble polymer, selected from a number of possible fillers: kollidon VA64 (vinyl copolymer irrolidone and vinyl acetate), kollidon 90F (high molecular weight polyvinylpyrrolidone with M.M. 1,000,000 to 1,500,000), ludipress (modified lactose), powdered sugar, isomaltose, 0-6% hydrophobic or inert polymer in order to achieve controlled release of the drug substance, where as the hydrophobic component uses compritol 888 ATO, Gatefosse (a composition of mono-, di- and triglycerides of behenic acid), as inert - kollidon SR, Basf (a mixture of polymers of polyvinylpyrrolidone and polyvinyl acetate). 2. Нанокомпозиция по п.1, в которой в качестве полимера использован полиэтиленгликоль (ПЭГ) (М.м. от 4000 до 8000), вносимый в систему при различных соотношениях с активным веществом.2. The nanocomposite according to claim 1, in which polyethylene glycol (PEG) is used as the polymer (M.m. from 4000 to 8000), introduced into the system at various ratios with the active substance. 3. Нанокомпозиция по п.1, в которой в качестве полимера использован поливинилпирролидон (ПВП) (М.м. от 7000 до 20000), вносимый в систему при различных соотношениях с активным веществом.3. The nanocomposition according to claim 1, in which polyvinylpyrrolidone (PVP) (M. m. From 7000 to 20,000) is used as a polymer, introduced into the system at various ratios with the active substance. 4. Нанокомпозиция по п.1, в которой в качестве полимера использован полисахарид арабиногалактан, вносимый в систему при различных соотношениях с активным веществом4. The nanocomposite according to claim 1, in which the arabinogalactan polysaccharide used as a polymer is introduced into the system at various ratios with the active substance
RU2007113156/15A 2007-04-09 2007-04-09 Solid nanocomposition for delivery of biologically active substances RU2351352C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2007113156/15A RU2351352C2 (en) 2007-04-09 2007-04-09 Solid nanocomposition for delivery of biologically active substances
PCT/RU2008/000201 WO2008123798A1 (en) 2007-04-09 2008-04-02 Solid nanocomposition for delivering biologically active substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2007113156/15A RU2351352C2 (en) 2007-04-09 2007-04-09 Solid nanocomposition for delivery of biologically active substances

Publications (2)

Publication Number Publication Date
RU2007113156A true RU2007113156A (en) 2008-10-27
RU2351352C2 RU2351352C2 (en) 2009-04-10

Family

ID=39831180

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007113156/15A RU2351352C2 (en) 2007-04-09 2007-04-09 Solid nanocomposition for delivery of biologically active substances

Country Status (2)

Country Link
RU (1) RU2351352C2 (en)
WO (1) WO2008123798A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (en) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
US8710027B2 (en) * 2012-04-10 2014-04-29 Flavitpure, Inc. Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
RU2533231C1 (en) * 2013-05-14 2014-11-20 Владимир Сергеевич Остронков Supramolecular complex, possessing anti-inflammatory and angioprotective activity and method of obtaining thereof
WO2021177930A1 (en) 2020-03-06 2021-09-10 Vyshnevskyy Ihor Anatoliyovych Pharmaceutical composition with increased solubility of gesperidine and method of its preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE183641T1 (en) * 1992-12-23 1999-09-15 Saitec Srl METHOD FOR PRODUCING MEDICINAL FORMS AND CONTROLLED RELEASE AND THE MEDICINAL FORMS OBTAINED
RU2276990C2 (en) * 2003-07-09 2006-05-27 Общество с ограниченной ответственностью "Компания "Чистая линия" Radioprotection composition and method for producing the composition

Also Published As

Publication number Publication date
WO2008123798A1 (en) 2008-10-16
RU2351352C2 (en) 2009-04-10

Similar Documents

Publication Publication Date Title
RU2485942C2 (en) Bupropion hydrobromide and therapeutic applications thereof
RU2013114406A (en) DRUG-RESISTANT DRUG FORM THAT CONTAINS AN Anionic POLYMER
ATE553754T1 (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED DELIVERY OF ACTIVE INGREDIENTS FOR ACTIVE INGREDIENTS WITH GOOD SOLUBILITY IN WATER
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
RU2011103085A (en) PHARMACEUTICAL DOSED FORM CONTAINING A POLYMERIC CARRIER COMPOSITION
RU2007113156A (en) SOLID NANOCOMPOSITION FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES
RU2014101227A (en) COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRICEUTIC MEDICINAL FORMS
WO2005084639A3 (en) Polymeric drug delivery system for hydrophobic drugs
CA2409828A1 (en) Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
RU2002135623A (en) RECIPE BASED ON HEPARIN, GLUCOSAMINOGLICAN OR HEPARINOID AND APPLICATION OF THE RECIPE AND ITS BASIS
RU2014101228A (en) COVERING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRICEUTIC MEDICINAL FORMS
WO2012041788A1 (en) Protective coatings for acidic active ingredients
CN110709068B (en) Improved sustained release high load pharmaceutical compositions
Lou et al. Temperature/pH dual responsive microgels of crosslinked poly (N‐vinylcaprolactam‐co‐undecenoic acid) as biocompatible materials for controlled release of doxorubicin
TR201820076T4 (en) Release of drug combinations.
NZ705802A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it.
WO2003011253A1 (en) Synergistic filler composition
Gwon et al. New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers
Williams et al. Polyethylene glycol-polyvinyl alcohol graft copolymer: a peroxide-free binder
KR20190111149A (en) Base for patch and patch using it
US20210347978A1 (en) Peroxide stable polymer composition and process for its preparation and applications thereof
WO2005023181A3 (en) Polymeric systems for controlled drug therapy
Bielas et al. Statistical copolymers of 2-(trimethylammonium) ethyl methacrylate as novel water soluble drug delivery systems
Wadher et al. FORMULATION AND EVALUATION OF GASTRORETANTIVE FLOATING TABLET USING EUDRAGIT RSPO WITH NATURAL POLYMERS
EP4013452A1 (en) Adhesive drug delivery film and a microparticle comprising thereof

Legal Events

Date Code Title Description
PC4A Invention patent assignment

Effective date: 20100216

PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20211027